IMS Health news and information

The Federal Trade Commission approved the sale of two of SDI Health's audit businesses to InVentiv Health, a divestiture required for Healthcare Technology Holdings subsidiary IMS Health to move forward with its acquisition of SDI Health.
FULL STORY »

IMS Health has acquired PharmARC Analytic Solutions, a Bangalore, India-based provider of commercial analytics and services to drug and medical products companies.
FULL STORY »

Consulting firm InVentiv Health plans to acquire the promotional and medical audit businesses of SDI Health, a healthcare analytics company.
FULL STORY »

The Federal Trade Commission has voted to accept a final settlement that will allow IMS Health, Danbury, Conn., to acquire its competitor in the healthcare analytics field, SDI Health, by spinning off two service lines to an approved buyer.
FULL STORY »

The Federal Trade Commission will require pharmaceutical market research firm IMS Health to sell off two business lines it would acquire in a deal to buy a competitor in the healthcare analytics field, SDI Health. IMS Health—which is owned by Fort Worth, Texas-based private-equity firm TPG...
FULL STORY »

The Federal Trade Commission announced that it would require pharmaceutical market research firm IMS Health to sell off two business lines it would acquire as a condition of allowing the firm to buy a competitor in the healthcare analytics field, SDI Health.
FULL STORY »

U.S. Rep. Edward Markey, a Massachusetts Democrat and co-chairman of the Congressional Bi-Partisan Privacy Caucus, has filed a formal resolution criticizing a recent Supreme Court decision that found that data-mining...
FULL STORY »

U.S. Rep. Edward Markey, a Massachusetts Democrat and co-chairman of the Congressional Bi-Partisan Privacy Caucus, has filed a formal resolution criticizing a recent Supreme Court decision that found that data-mining...
FULL STORY »

The U.S. Supreme Court has vacated a decision by the 1st U.S. Circuit Court of Appeals that upheld a Maine law constraining the use of prescription-drug data for marketing pharmaceuticals to physicians.
FULL STORY »

Any lawmaker who aims to slow the rising cost of healthcare by restricting manufacturers' ability to market new and more expensive wares had better be prepared to argue their point before a skeptical Supreme Court.
FULL STORY »